Triple Impact Capital — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Kanvas Bio operates a full-stack microbiome drug discovery platform, using a spatial mapping engine to image host-microbiome interactions and in-house manufacturing to produce live biotherapeutics.
BiotechDeep TechHealthtechMonmouth Junction, US
Matthew Cheng(Executive Officer, Director)Hao Shi(Executive Officer, Director)Iwijn De Vlaminck(Executive Officer, Director)
BoardJason Pontin(Director)in
Board seatJustin Smithline· per SEC Form D · $12M raise · filed Jun 2023
Co-investorsBascom VenturesBoutique Venture PartnersDCVC (Data Collective)FemHealth VenturesGermin8 VenturesKicker Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.